Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy

We aimed to compare long-term mortality trends in end-stage renal disease versus general population controls after accounting for differences in age, sex and comorbidity. Cohorts of 45,000 patients starting maintenance renal replacement therapy (RRT) and 5·6 million hospital controls were identified...

Full description

Bibliographic Details
Main Authors: Storey, B, Staplin, N, Harper, C, Haynes, R, Winearls, C, Goldacre, R, Emberson, J, Goldacre, M, Baigent, C, Landray, M, Herrington, W
Format: Journal article
Published: Elsevier 2018
_version_ 1797077777765105664
author Storey, B
Staplin, N
Harper, C
Haynes, R
Winearls, C
Goldacre, R
Emberson, J
Goldacre, M
Baigent, C
Landray, M
Herrington, W
author_facet Storey, B
Staplin, N
Harper, C
Haynes, R
Winearls, C
Goldacre, R
Emberson, J
Goldacre, M
Baigent, C
Landray, M
Herrington, W
author_sort Storey, B
collection OXFORD
description We aimed to compare long-term mortality trends in end-stage renal disease versus general population controls after accounting for differences in age, sex and comorbidity. Cohorts of 45,000 patients starting maintenance renal replacement therapy (RRT) and 5·6 million hospital controls were identified from two large electronic hospital inpatient datasets: the Oxford Record Linkage Study (1965-1999) and all-England Hospital Episode Statistics (2000-2011). All-cause and cause-specific 3-year mortality rates for both populations were calculated using Poisson regression and standardized to the age, sex, comorbidity structure of an ‘average’ 1970-2008 RRT population. The median age at initiation of RRT in 1970-1990 was 49y (interquartile cut-offs 36–60y) and 63y (49–73y) by 2006-2008. Over that period, there were increases in the prevalence of vascular disease (from 10·0 to 28·3%) and diabetes (from 6·7 to 34·3%). After accounting for age, sex and comorbidity differences, standardized 3-year all-cause mortality rates in treated ESRD patients between 1970 and 2011 fell by about one-half (relative decline 51%, 95%CI 41–60%) steeper than the one-third decline (34%, 95%CI 31–36%) observed in the general population. Declines in 3-year mortality rates were evident among those who received a kidney transplant and those who remained on dialysis, and among those with and without diabetes. In conclusion, the full extent of mortality rate declines among RRT patients since 1970 is only apparent when changes in comorbidity over time are taken into account. This approach suggests mortality rates in RRT patients have declined faster than the general population.
first_indexed 2024-03-07T00:22:52Z
format Journal article
id oxford-uuid:7d239c54-f82d-4969-b864-90a14b88d603
institution University of Oxford
last_indexed 2024-03-07T00:22:52Z
publishDate 2018
publisher Elsevier
record_format dspace
spelling oxford-uuid:7d239c54-f82d-4969-b864-90a14b88d6032022-03-26T21:01:38ZDeclining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7d239c54-f82d-4969-b864-90a14b88d603Symplectic Elements at OxfordElsevier2018Storey, BStaplin, NHarper, CHaynes, RWinearls, CGoldacre, REmberson, JGoldacre, MBaigent, CLandray, MHerrington, WWe aimed to compare long-term mortality trends in end-stage renal disease versus general population controls after accounting for differences in age, sex and comorbidity. Cohorts of 45,000 patients starting maintenance renal replacement therapy (RRT) and 5·6 million hospital controls were identified from two large electronic hospital inpatient datasets: the Oxford Record Linkage Study (1965-1999) and all-England Hospital Episode Statistics (2000-2011). All-cause and cause-specific 3-year mortality rates for both populations were calculated using Poisson regression and standardized to the age, sex, comorbidity structure of an ‘average’ 1970-2008 RRT population. The median age at initiation of RRT in 1970-1990 was 49y (interquartile cut-offs 36–60y) and 63y (49–73y) by 2006-2008. Over that period, there were increases in the prevalence of vascular disease (from 10·0 to 28·3%) and diabetes (from 6·7 to 34·3%). After accounting for age, sex and comorbidity differences, standardized 3-year all-cause mortality rates in treated ESRD patients between 1970 and 2011 fell by about one-half (relative decline 51%, 95%CI 41–60%) steeper than the one-third decline (34%, 95%CI 31–36%) observed in the general population. Declines in 3-year mortality rates were evident among those who received a kidney transplant and those who remained on dialysis, and among those with and without diabetes. In conclusion, the full extent of mortality rate declines among RRT patients since 1970 is only apparent when changes in comorbidity over time are taken into account. This approach suggests mortality rates in RRT patients have declined faster than the general population.
spellingShingle Storey, B
Staplin, N
Harper, C
Haynes, R
Winearls, C
Goldacre, R
Emberson, J
Goldacre, M
Baigent, C
Landray, M
Herrington, W
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
title Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
title_full Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
title_fullStr Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
title_full_unstemmed Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
title_short Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
title_sort declining comorbidity adjusted mortality rates in english patients receiving maintenance renal replacement therapy
work_keys_str_mv AT storeyb decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT staplinn decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT harperc decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT haynesr decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT winearlsc decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT goldacrer decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT embersonj decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT goldacrem decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT baigentc decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT landraym decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy
AT herringtonw decliningcomorbidityadjustedmortalityratesinenglishpatientsreceivingmaintenancerenalreplacementtherapy